- Home
- BDTX vs CRNX Comparison
BDTX vs CRNX Comparison
Compare BDTX & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- CRNX
- Stock Information
- Founded
- BDTX 2014
- CRNX 2008
- Country
- BDTX United States
- CRNX United States
- Employees
- BDTX N/A
- CRNX N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- CRNX Health Care
- Exchange
- BDTX Nasdaq
- CRNX Nasdaq
- Market Cap
- BDTX 132.5M
- CRNX 2.8B
- IPO Year
- BDTX 2020
- CRNX 2018
- Fundamental
- Price
- BDTX $2.58
- CRNX $30.00
- Analyst Decision
- BDTX Strong Buy
- CRNX Strong Buy
- Analyst Count
- BDTX 6
- CRNX 10
- Target Price
- BDTX $14.83
- CRNX $75.00
- AVG Volume (30 Days)
- BDTX 1.3M
- CRNX 646.9K
- Earning Date
- BDTX 08-05-2025
- CRNX 08-07-2025
- Dividend Yield
- BDTX N/A
- CRNX N/A
- EPS Growth
- BDTX N/A
- CRNX N/A
- EPS
- BDTX 0.09
- CRNX N/A
- Revenue
- BDTX $70,000,000.00
- CRNX $760,000.00
- Revenue This Year
- BDTX N/A
- CRNX $402.12
- Revenue Next Year
- BDTX N/A
- CRNX $770.88
- P/E Ratio
- BDTX $29.29
- CRNX N/A
- Revenue Growth
- BDTX N/A
- CRNX N/A
- 52 Week Low
- BDTX $1.20
- CRNX $24.10
- 52 Week High
- BDTX $6.75
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- BDTX 60.65
- CRNX 44.17
- Support Level
- BDTX $2.43
- CRNX $28.34
- Resistance Level
- BDTX $2.72
- CRNX $30.01
- Average True Range (ATR)
- BDTX 0.18
- CRNX 1.07
- MACD
- BDTX -0.00
- CRNX -0.17
- Stochastic Oscillator
- BDTX 76.11
- CRNX 36.41
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.